No­vo Nordisk to dis­con­tin­ue long-act­ing in­sulin Lev­emir next year amid in­com­ing 65% price cut

In­sulin pow­er­house No­vo Nordisk will dis­con­tin­ue its long-act­ing in­sulin Lev­emir in the US next year amid an­tic­i­pat­ed sup­ply dis­rup­tions, a 65% price cut and as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER